Colgate-Palmolive's (CL) Q4 organic sales growth was weaker than expected, but Morgan Stanley remains optimistic about its long-term trajectory, expecting the company to outpace most peers in organic sales growth.
The firm noted in a Monday note that Colgate-Palmolive's 2025 EPS guidance was better than expected, driven by pricing strategies and past reinvestment. However, cost pressures and foreign exchange risks make the lower end of guidance seem more achievable.
"We are more bullish than most investors we spoke with and believe that Colgate-Palmolive will be a 4% organic sales growth company going forward, supported by pricing power and market share gains," Morgan Stanley added.
The firm added that Colgate-Palmolive's global toothpaste market share dipped slightly due to foreign exchange-driven mix effects, while Hill's Pet Nutrition contributed to overall growth, despite European weakness.
Morgan Stanley reduced its price target of Colgate-Palmolive's stock to $104 from $111 and has an overweight rating.
Price: 86.33, Change: -0.37, Percent Change: -0.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。